Connect with us
Researchers at the Institute of Biomedicine of Seville identified molecular mechanisms explaining aggressive neuroblastoma. Dysregulation of Rho GTPase signaling, especially reduced Cdc42 activity driven by ARHGAP31,...
Enlivex Therapeutics stock attracts speculative biotech investors amid volatility, weak performance, and limited institutional coverage. Shares near $1.40–$1.50 reflect a yearlong decline of roughly 35–40 percent...
Europe has launched the Joint Action on Personalized Cancer Medicine, involving 29 countries and over 140 partners, to improve prevention, diagnosis, and treatment through data-driven, individualized...
Researchers at Scripps Research and MIT developed a DNA-based scaffold for HIV vaccines that avoids unwanted immune responses triggered by protein scaffolds. Using DNA origami nanoparticles,...
Bioceres shares fell 36% to US$0.84, entering penny-stock territory and nearing delisting risk. Once valued near US$900 million, the company now sits around US$53 million. Financial...
ByBug, a Chilean biotech startup, uses genetically edited black soldier fly larvae as biofactories to produce oral therapeutic proteins for animal health. The approach cuts costs...
Founded in 2024, Twogee Biotech develops customer-specific enzyme solutions that convert low-value biomass residues into sustainable second-generation raw materials. Using a predictive, industry-oriented platform, the company...
CIPM’s January 28, 2026 meeting proposed full or partial funding for three new drugs, including an orphan drug, plus multiple indication expansions. Decisions covered rare diseases,...
Eli Lilly has partnered with Dresden-based Seamless Therapeutics to develop a recombinase-based gene therapy for genetically caused hearing loss. Seamless will engineer precise recombinases, while Lilly...
BioNTech shares are off to a strong start in 2026, gaining over 21 percent in both European and U.S. markets. Analysts remain optimistic, with most recommending...